謝宗涵

Louise Hsieh謝宗涵  助研究員
生技與藥物研究所
Email: louisehsieh@nhri.edu.tw

 

EDUCATION

  • PhD (Dr. phil. nat), Pharmacy, Johann Wolfgang Goethe University (2017)
  • MSc, Pharmacy, National Taiwan University (2009)
  • BSc, Biochemical Science and Technology, National Taiwan University (2006)

PROFESSIONAL EXPERIENCES

  • Assistant investigator, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, since 06. 2024
  • Postdoctoral fellow, Institute of Molecular Biology, Academia Sinica, 08. 2022 – 06. 2024
  • Research fellow on host-pathogen interactions, Department of Microbial Science, University of Surrey, 09. 2018 – 06. 2022
  • Postdoctoral fellow, Pharmacenter Frankfurt, Johann Wolfgang Goethe University Hospital,03. 2017 – 06. 2018

RESEARCH INTERESTS

Chronic kidney disease (CKD) is a complex, progress condition with the nature of losing renal functions. It affects more than 10% of the global population with a gradual increasing prevalence. Dr. Hsieh would like to provide innovative new drugs, including small molecules and RNA-based therapeutics, to reverse profibrotic state of diseased kidneys and restore the function of the filtration barrier. Primary focus includes the homeostasis of glomerular basement membrane and the alteration of tubular epithelial cells in the diseased animal models and primary cell culture.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

Dr. Hsieh is a biochemist with robust training in pharmaceutical research and matrix pathobiology. She has involved in tackling several diseases including sterile renal inflammation and infectious disease such as Buruli ulcer and mPox. The work related to Buruli ulcer has successfully identified two druggable targets with positive outcome in the tested animal model and cell-based studies.

SELECTED PUBLICATIONS(since 2015)

  • Hsieh LT, Hall BS, Newcombe J, Mendum TA, Umrania Y, Deery MJ, Shi WQ, Salguero FJ, Simmonds RE. Mycolactone causes catastrophic Sec61- dependent loss of the endothelial glycocalyx and basement membrane: a new indirect mechanism driving tissue necrosis in Mycobacterium ulcerans infection. eLife. 2023 May.
  • Hsieh LT, Dos Santos SJ, Hall BS, Ogbechi J, Loglo AD, Salguero FJ, Ruf MT, Pluschke G, Simmonds RE. Aberrant stromal tissue factor localisation and mycolactone-driven vascular dysfunction, exacerbated by IL-1β, are linked to fibrin formation in Buruli ulcer lesions. PLoS Pathog. 2022 Jan 31;18(1):e1010280.
  • Hall BS, Hsieh LT, Sacre S, Simmonds RE. The one that got away: how macrophage-derived IL-1beta escapes the mycolactone-dependent Sec61 blockade in Buruli ulcer. Front. Immunol. 2022 Jan 26;12:788146.
  • Hall BS, Dos Santos SJ, Hsieh LT, Manifava M, Ruf MT, Pluschke G, Ktistakis N, Simmonds RE. Sec61 inhibition by mycolactone induces protective autophagic response controlled by EIF2S1-dependent translation that does not require ULK1 activity Autophagy. Autophagy. 2021 Aug 23;1-19.
  • Poluzzi C, Nastase MV, Zeng-Brouwers J, Roedig H, Hsieh LT, Michaelis JB, Buhl EM, Rezende F, Manavski Y, Bleich A, Boor P, Brandes RP, Pfeilschifter J, Stelzer EHK, Münch C, Dikic I, Brandts C, Iozzo RV, Wygrecka M, Schaefer L. Biglycan evokes autophagy in macrophages via a novel CD44/Toll-like receptor 4 signaling axis in ischemia/reperfusion injury. Kidney Int. 2019 Mar; 95(3):540- 562.
  • Roedig H, Nastase MV, Frey H, Moreth K, Zeng-Brouwers J, Poluzzi C, Hsieh LT, Brandts C, Fulda S, Wygrecka M, Schaefer L. Biglycan is a new high-affinity ligand for CD14 in macrophages. Matrix Biol. 2019 Apr; 77:4-22.
  • Nastase MV, Janicova A, Roedig H, Hsieh LT, Wygrecka M, Schaefer L. Small leucine-rich proteoglycans in renal inflammation: two sides of the coin. J Histochem Cytochem. 2018 Apr; 66(4): 261–272.
  • Hsieh LT, Nastase MV, Roedig H, Zeng-Brouwers J, Poluzzi C, Schwalm S, Fork C, Tredup C, Brandes RP, Wygrecka M, Huwiler A, Pfeilschifter J, Schaefer L. Biglycan- and sphingosine kinase-1 signaling crosstalk regulates the synthesis of macrophage chemoattractants. Int J Mol Sci. 2017 Mar; 18(3):595.
  • Aglan A, Longen S, Dehne N, Köhler Y, Hassan M, Beck M, Tredup C, Meike Boosen M, Hsieh LT, Schaefer L, Beck KF, Pfeilschifter J. Nitric oxide mediates prolyl hydroxylase 3 expression in mesangial cells and in glomerulonephritis. J Mol Med. 2017 Jan; 95(3):257-71.
  • Frey H, Moreth K, Hsieh LT, Zeng-Brouwers J, Rathkolb B, Fuchs H, Gailus Durner V, Iozzo RV, Hrabě de Angelis M, Schaefer L. A novel biological function for soluble biglycan: Induction of erythropoietin production and polycythemia. Glycoconj J. 2017 Jun;34(3):393-404.
  • Nastase MV, Zeng-Brouwers J, Frey H, Hsieh LT, Poluzzi C, Beckmann J, Schroeder N, Pfeilschifter J, Lopez-Mosqueda J, Mersmann J, Ikeda F, Iozzo RV, Dikic I, Schaefer L. An Essential Role for SHARPIN in the Regulation of Caspase 1 Activity in Sepsis. Am J Pathol. 2016 May; 186(5):1206-20.
  • Hsieh LT, Frey H, Nastase MV, Tredup C, Hoffmann A, Poluzzi C, Zeng-Brouwers J, Manon-Jensen T, Schröder K, Brandes RP, Iozzo RV, Schaefer L. Bimodal role of NADPH oxidases in the regulation of biglycan-triggered IL-1β synthesis. Matrix Biol. 2016 Jan; 49:61-81.
  • Fuchs S, Hsieh LT, Saarberg W, Erdelmeier CA, Wichelhaus TA, Schaefer L, Koch E, Fürst R. Haemanthus coccineus extract and its main bioactive component narciclasine display profound anti-inflammatory activities in vitro and in vivo. J Cell Mol Med. 2015 May; 19(5):1021-32.

Comments are closed.